Galmed Pharmaceuticals Ltd. (GLMD) Sees Strong Trading Volume
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) saw an uptick in trading volume on Wednesday . 412,206 shares were traded during mid-day trading, an increase of 414% from the previous session’s volume of 80,214 shares.The stock last traded at $4.61 and had previously closed at $4.61.
Several analysts have recently issued reports on the company. FBR & Co set a $20.00 price objective on Galmed Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, August 5th. Maxim Group reissued a “buy” rating and set a $9.00 target price (down previously from $24.00) on shares of Galmed Pharmaceuticals in a research report on Monday, August 1st. Zacks Investment Research downgraded Galmed Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 19th. Roth Capital reissued a “buy” rating and set a $6.00 target price on shares of Galmed Pharmaceuticals in a research report on Wednesday, July 6th. Finally, HC Wainwright reissued a “buy” rating on shares of Galmed Pharmaceuticals in a research report on Thursday, June 30th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $12.35.
The firm’s market cap is $51.51 million. The company’s 50-day moving average is $3.96 and its 200 day moving average is $4.68.
Galmed Pharmaceuticals (NASDAQ:GLMD) last issued its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.35) by $0.04. On average, analysts expect that Galmed Pharmaceuticals Ltd. will post ($1.51) earnings per share for the current fiscal year.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.
Receive News & Ratings for Galmed Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.